Abstracts tagged "sialoadenitis and tobacco use"

Abstract Number: 2662 • 2016 ACR/ARHP Annual Meeting
Effect of Tobacco Smoking on the Clinical, Histopathological, and Serological Manifestations of SjöGren’s Syndrome
Astrid Rasmussen¹, Donald U. Stone², Dustin Fife³, Michael Brown⁴, Keith Earley⁵, Lida Radfar⁶, C. Erick Kaufman⁷, David M. Lewis⁸, Nelson L. Rhodus⁹, Barbara M. Segal¹⁰, Daniel J Wallace¹¹, Michael Weisman¹², Swamy Venuturupalli¹³, Michael T. Brennan¹⁴, Christopher J Lessard³, Courtney G. Montgomery¹⁵, R. Hal Scofield¹⁵ and Kathy L. Sivils¹⁵, ¹Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, USA, Oklahoma City, OK, ²King Khaled Eye Specialist Hospital, Riyadh, Saudi Arabia, ³Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁴Pfizer Inc., Groton, CT, ⁵59th Medical Wing, US Air Force, San Antonio, TX, ⁶Oral Diagnosis and Radiology Department, University of Oklahoma College of Dentistry, Oklahoma City, OK, ⁷Medicine, University of Oklahoam Health Sciences Center, Oklahoma City, OK, ⁸Department of Oral and Maxillofacial Pathology, University of Oklahoma College of Dentistry, Oklahoma City, OK, ⁹Department of Diagnostic and Biological Sciences, University of Minnesota School of Dentistry, Minneapolis, MN, ¹⁰Division of Rheumatology, University of Minnesota Medical School, Minneapolis, MN, ¹¹Division of Rheumatology, Cedars-Sinai Medical Center, Los Angeles, CA, ¹²Rheumatology, Cedars-Sinai Medical Center, Los Angeles, CA, ¹³Division of Rheumatology, Cedars Sinai Medical Center, Los Angeles, CA, ¹⁴Department of Oral Medicine, Carolinas Medical Center, Charlotte, NC, ¹⁵Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK
Background/Purpose: To assess the prevalence of smoking in patients with Sjögren’s syndrome (SS) and non-Sjögren’s sicca (non-SS sicca), and the association of smoking habits with…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].